MIV Therapeutics Announces Availability of Updated Investor Fact Sheet; Company Fact Sheet Outlines Proprietary Solutions for Cardiovascular Disease and Novel Stroke-Prevention Devices.

VANCOUVER, British Columbia -- MIV Therapeutics, Inc. (OTCBB:MIVT) (FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems, has announced the availability of an updated Investor Fact Sheet that outlines the Company's proprietary and novel technologies, and its research programs to develop improved coatings for drug-eluting vascular stents and other implantable medical devices.

MIVT is also developing a novel stroke-prevention device through its wholly owned subsidiary, SagaX Inc., located in Herzlyia, Israel. SagaX is a developer of advanced biomedical technology, including the Aortic Embolic Protection Device (AEPD). The AEPD is a unique and proprietary filter/deflector device designed specifically to prevent cardioembolic stroke following heart surgery. SagaX Inc. is also developing further generations of anti-embolic devices.

MIVT recently announced that SagaX has accelerated development of the stroke-preventing AEPD implantable device, and may have the device ready for clinical use within 14 months, subject to regulatory approval.

The Investor Fact Sheet can be viewed at http://www.trilogy-capital.com/tcp/mivt/factsheet.html.

About MIV Therapeutics, Inc.

MIV Therapeutics, Inc. is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting application on cardiovascular stents and for application on other implantable medical devices. The Company's ultra-thin coating formulation is designed primarily to protect surrounding tissue from the chemical interaction with metal stents. The Company's unique ultra-thin coating has been derived from a biocompatible material called hydroxyapatite (HAp) that during in-vivo animal trials demonstrated excellent safety and superior healing properties pursued by the science in the field of advanced implantable drug delivery systems. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth. It is widely used as a bone substitute material and for coating implantable fixation devices in orthopedic, dental and other applications. The Company's novel drug eluting technologies based on Hydroxyapatite provide an attractive alternative solution to polymer-based drug eluting coatings currently in the stent market. The Company's drug eluting coating is designed to suit a broad range of implantable medical devices which may benefit from a highly customizable drug release profile. MIVT reached a Collaborative Research Agreement (CRA) with the University of British Columbia and supported a research and development grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) in 2002 for the development of Hydroxyapatite as a drug-eluting coating. In December 2004 MIVT received a Government grant for the research program titled "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents" under the National Research Council -- Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship the Company will progress to the development stage, which is expected to finalize the drug-eluting research and development Program. For more information, please visit: http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. MIVT is also traded on the Frankfurt Stock Exchange under the ticker symbol MIV.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.